About

Pfizer is offering competitive grants to support research projects that advance safe and timely COVID‑19 treatment through artificial intelligence (AI) and advanced clinical decision support systems. The program prioritizes initiatives that improve access to antiviral therapy, optimize patient eligibility assessment, and enhance management of drug–drug interactions to ensure effective disease management. A particular focus is placed on the use of Nirmatrelvir/Ritonavir for high‑risk patients, emphasizing early treatment within five days of symptom onset to reduce severe outcomes, hospitalization, and mortality. Projects may request up to $500,000 USD in funding, with a maximum duration of two years. The geographic scope includes Australia, Canada, China, Germany, Greece, Japan, Korea, and Taiwan, and supported activities must align with the program’s goals of leveraging AI and clinical tools to improve COVID‑19 treatment outcomes.

Eligibility

Applications are open to organizations with a Principal Investigator based in one of the eligible countries. Grants are not available to individuals or independent medical practice groups unaffiliated with hospitals, academic institutions, or professional societies. The Principal Investigator must hold a medical, postdoctoral, advanced nursing, pharmacy, physiotherapy, or social work degree and be employed or contracted by the requesting organization. Where multiple institutions are involved, each must have a defined role, with the lead organization serving as the primary applicant. The requesting organization must also be legally able to receive funding directly from Pfizer Inc., and applicants are encouraged to verify their eligibility before submission.

Post Date: May 21, 2026